Pulse intravenous cyclophosphamide therapy in pemphigus

Mary E. Fleischli, Rachel H. Valck, Amit G. Pandya

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background: Adjuvant therapy is commonly used in pemphigus to mitigate the high morbidity and mortality associated with the use of corticosteroids and improve disease control. However, these adjuvant agents are not without adverse effects of their own, including an increased risk of malignancy with the use of oral immunosuppressives. Intravenous pulse cyclophosphamide, which may be more efficacious and less toxic than oral immunosuppressives, has been used successfully in the treatment of pemphigus. Objective: To review 9 patients with severe or previously recalcitrant pemphigus who were treated with intravenous pulse cyclophosphamide therapy. Results: Six of the 9 patients responded to therapy, with 2 patients achieving remission from skin lesions. Five patients were able to decrease their daily dose of prednisone, and 1 was able to discontinue the use of prednisone completely. Most patients experienced minimal or no adverse effects. Conclusions: Intravenous pulse cyclophosphamide may be an alternative treatment option in patients with pemphigus recalcitrant to standard therapy. The decreased cumulative dose of cyclophosphamide observed with monthly pulse doses may reduce the incidence of secondary malignancies when compared with continuous oral therapy. Controlled trials are needed to further evaluate the efficacy of this mode of therapy.

Original languageEnglish (US)
Pages (from-to)57-61
Number of pages5
JournalArchives of Dermatology
Volume135
Issue number1
DOIs
StatePublished - Jan 1999

Fingerprint

Pemphigus
Cyclophosphamide
Therapeutics
Immunosuppressive Agents
Prednisone
Poisons
Neoplasms
Adrenal Cortex Hormones
Morbidity
Skin
Mortality
Incidence

ASJC Scopus subject areas

  • Dermatology

Cite this

Pulse intravenous cyclophosphamide therapy in pemphigus. / Fleischli, Mary E.; Valck, Rachel H.; Pandya, Amit G.

In: Archives of Dermatology, Vol. 135, No. 1, 01.1999, p. 57-61.

Research output: Contribution to journalArticle

Fleischli, Mary E. ; Valck, Rachel H. ; Pandya, Amit G. / Pulse intravenous cyclophosphamide therapy in pemphigus. In: Archives of Dermatology. 1999 ; Vol. 135, No. 1. pp. 57-61.
@article{7da548372a474f97a7e9793c3cb956ca,
title = "Pulse intravenous cyclophosphamide therapy in pemphigus",
abstract = "Background: Adjuvant therapy is commonly used in pemphigus to mitigate the high morbidity and mortality associated with the use of corticosteroids and improve disease control. However, these adjuvant agents are not without adverse effects of their own, including an increased risk of malignancy with the use of oral immunosuppressives. Intravenous pulse cyclophosphamide, which may be more efficacious and less toxic than oral immunosuppressives, has been used successfully in the treatment of pemphigus. Objective: To review 9 patients with severe or previously recalcitrant pemphigus who were treated with intravenous pulse cyclophosphamide therapy. Results: Six of the 9 patients responded to therapy, with 2 patients achieving remission from skin lesions. Five patients were able to decrease their daily dose of prednisone, and 1 was able to discontinue the use of prednisone completely. Most patients experienced minimal or no adverse effects. Conclusions: Intravenous pulse cyclophosphamide may be an alternative treatment option in patients with pemphigus recalcitrant to standard therapy. The decreased cumulative dose of cyclophosphamide observed with monthly pulse doses may reduce the incidence of secondary malignancies when compared with continuous oral therapy. Controlled trials are needed to further evaluate the efficacy of this mode of therapy.",
author = "Fleischli, {Mary E.} and Valck, {Rachel H.} and Pandya, {Amit G.}",
year = "1999",
month = "1",
doi = "10.1001/archderm.135.1.57",
language = "English (US)",
volume = "135",
pages = "57--61",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Pulse intravenous cyclophosphamide therapy in pemphigus

AU - Fleischli, Mary E.

AU - Valck, Rachel H.

AU - Pandya, Amit G.

PY - 1999/1

Y1 - 1999/1

N2 - Background: Adjuvant therapy is commonly used in pemphigus to mitigate the high morbidity and mortality associated with the use of corticosteroids and improve disease control. However, these adjuvant agents are not without adverse effects of their own, including an increased risk of malignancy with the use of oral immunosuppressives. Intravenous pulse cyclophosphamide, which may be more efficacious and less toxic than oral immunosuppressives, has been used successfully in the treatment of pemphigus. Objective: To review 9 patients with severe or previously recalcitrant pemphigus who were treated with intravenous pulse cyclophosphamide therapy. Results: Six of the 9 patients responded to therapy, with 2 patients achieving remission from skin lesions. Five patients were able to decrease their daily dose of prednisone, and 1 was able to discontinue the use of prednisone completely. Most patients experienced minimal or no adverse effects. Conclusions: Intravenous pulse cyclophosphamide may be an alternative treatment option in patients with pemphigus recalcitrant to standard therapy. The decreased cumulative dose of cyclophosphamide observed with monthly pulse doses may reduce the incidence of secondary malignancies when compared with continuous oral therapy. Controlled trials are needed to further evaluate the efficacy of this mode of therapy.

AB - Background: Adjuvant therapy is commonly used in pemphigus to mitigate the high morbidity and mortality associated with the use of corticosteroids and improve disease control. However, these adjuvant agents are not without adverse effects of their own, including an increased risk of malignancy with the use of oral immunosuppressives. Intravenous pulse cyclophosphamide, which may be more efficacious and less toxic than oral immunosuppressives, has been used successfully in the treatment of pemphigus. Objective: To review 9 patients with severe or previously recalcitrant pemphigus who were treated with intravenous pulse cyclophosphamide therapy. Results: Six of the 9 patients responded to therapy, with 2 patients achieving remission from skin lesions. Five patients were able to decrease their daily dose of prednisone, and 1 was able to discontinue the use of prednisone completely. Most patients experienced minimal or no adverse effects. Conclusions: Intravenous pulse cyclophosphamide may be an alternative treatment option in patients with pemphigus recalcitrant to standard therapy. The decreased cumulative dose of cyclophosphamide observed with monthly pulse doses may reduce the incidence of secondary malignancies when compared with continuous oral therapy. Controlled trials are needed to further evaluate the efficacy of this mode of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032908511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032908511&partnerID=8YFLogxK

U2 - 10.1001/archderm.135.1.57

DO - 10.1001/archderm.135.1.57

M3 - Article

C2 - 9923782

AN - SCOPUS:0032908511

VL - 135

SP - 57

EP - 61

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 1

ER -